Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

4.340 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
This Stock Is Up 74% This Year: Is It Too Late to Buy? ↗
The biotech is clearly innovative, but sometimes that's not enough. 
Via The Motley Fool
IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) Passes Mark Minervini’s Trend Template and High-Growth Momentum Screen ↗
Via Chartmill
Iovance Biotherapeutics (NASDAQ:IOVA) Reports Q1 Revenue Beat and Raised Guidance, Yet Stock Slips Pre-Market ↗
Via Chartmill
News headline image
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 2026. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
From Biotech Insider
Via GlobeNewswire
News headline image
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For? ↗
Tread carefully, but certain factors make this speculative biotech play stand out. 
Via The Motley Fool
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
Via Investor Brand Network
News headline image
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
From BioMedWire
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Present at Upcoming Conference
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance (IOVA) Q1 2026 Earnings Transcript ↗
Iovance (IOVA) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street ↗
It could just as well drop by 50% -- or more -- over the next 12 months. 
Via The Motley Fool
Topics Death
News headline image
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? ↗
This oncology specialist has proven innovative abilities. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗
Via MarketBeat
News headline image
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 ↗
If you decide to invest in this company, it's probably best to start small. 
Via The Motley Fool
News headline image
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗
Investors are increasingly comparing ImmunityBio and Iovance Biotherapeutics as both cancer drug developers move into catalyst-heavy phases. 
Via Stocktwits
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why ↗
Chardan cited operational efficiencies and expected margin lift as Lifileucel manufacturing is fully internalized. 
Via Stocktwits
Topics Earnings
Curious about the most active stocks on Tuesday? ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.